Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Selective Serotonin Reuptake Inhibitor Clear all
Completed Phase 2Phase 3 Interventional

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

NCT01318434
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo
Drug
Lead sponsor
Euthymics BioScience, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
43
States / cities
Arcadia, California • Beverly Hills, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Phase 1 Interventional

A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin

NCT01366664
View directory record Official record
Conditions
Ejaculation
Interventions
Treatment sequence 2, Treatment sequence 1
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Anniston, Alabama • Tempe, Arizona • Costa Mesa, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression

NCT00093847
View directory record Official record
Conditions
Depression
Interventions
S-adenosyl methione (SAMe), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 12, 2014 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

NCT00633399
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Sep 17, 2026, 9:37 PM EDT
Completed No phase listed Observational

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

NCT05841030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
No Intervention
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Homewood, Alabama • California City, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Lexapro and Pramipexole and to Treat Major Depression

NCT00086307
View directory record Official record
Conditions
Major Depression
Interventions
Pramipexole, Escitalopram
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 27, 2013 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

NCT00840034
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Sep 17, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Results available

Fluoxetine for Visual Recovery After Ischemic Stroke

NCT02737930
View directory record Official record
Conditions
Acute Stroke, Visual Field Loss
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Bogachan Sahin
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)

NCT00249405
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse
Interventions
Citalopram + MI, Placebo + MI
Drug · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
21 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Sep 17, 2026, 9:37 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Partners in Caring for Anxious Youth

NCT04598230
View directory record Official record
Conditions
Anxiety, Separation, Anxiety, Generalized, Anxiety, Social
Interventions
Cognitive Behavioral Therapy (CBT), Combination therapy (COMB)
Behavioral · Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
7 Years to 17 Years
Enrollment
468 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Phase 4 Interventional

Major Depressive Disorder Study In Adults

NCT00049972
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
paroxetine CR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
71
States / cities
Birmingham, Alabama • Fairfield, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Not applicable Interventional

Efficacy of Exercise for Sexual Side Effects of Antidepressants

NCT01189825
View directory record Official record
Conditions
Sexual Dysfunction
Interventions
Exercise
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Phase 4 Interventional

Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo

NCT00334048
View directory record Official record
Conditions
Sexual Dysfunction
Interventions
Ropinirole (Requip)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Sep 17, 2026, 9:37 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

NCT06704594
View directory record Official record
Conditions
Premenstrual Dysphoric Disorder (PMDD)
Interventions
sertraline 50 mg daily, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 17, 2026, 9:37 PM EDT
Terminated Phase 1 Interventional

Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor

NCT01299415
View directory record Official record
Conditions
Solid Tumors
Interventions
Vadimezan™
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
4
States / cities
Indianapolis, Indiana • Minneapolis, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)

NCT01674361
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Bitopertin, Placebo, SSRI
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
27
States / cities
Oceanside, California • Stanford, California • New Haven, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone

NCT02015546
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Vilazodone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 17, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Results available

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

NCT01103180
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor

NCT01185340
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
20
States / cities
Garden Grove, California • Oakland, California • Temecula, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 17, 2026, 9:37 PM EDT
Recruiting Not applicable Interventional

Biomarkers in the Retina for Prognosticating Mental Health Treatments

NCT06363968
View directory record Official record
Conditions
PTSD, Posttraumatic Stress Disorder
Interventions
RETeval
Device
Lead sponsor
VA Puget Sound Health Care System
Federal
Eligibility
21 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Sep 17, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

NCT01275248
View directory record Official record
Conditions
Obsessive-compulsive Disorder
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
Transcept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Beverly Hills, California • Imperial, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

NCT01173601
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Irvine, California • La Habra, California • Redlands, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 17, 2026, 9:37 PM EDT
Completed Phase 4 Interventional

Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder

NCT00025740
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
clonazepam and paroxetine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 9:37 PM EDT
Withdrawn No phase listed Observational

Sleep Quality, Cognitive Performance, and Computerized Cognitive Training

NCT06328140
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Psychosis
Interventions
Lurasidone, FDA Approved antidepressant treatment
Drug
Lead sponsor
George West Mental Health Foundation d/b/a Skyland Trail
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 17, 2026, 9:37 PM EDT